Palatin Technologies, Inc. (NYSE:PTN) has a beta value of 1.55 and has seen 2,390,919 shares traded in the last trading session. The company, currently valued at $120.77 Million, closed the last trade at $0.5268 per share which meant it lost $0 on the day or 2.27% during that session. The PTN stock price is -129.69% off its 52-week high price of $1.21 and 31.66% above the 52-week low of $0.36. If we look at the company’s 10-day average daily trading volume, we find that it stood at 9.73 Million shares traded. The 3-month trading volume is 2.4 Million shares.

The consensus among analysts is that Palatin Technologies, Inc. (PTN) is a Buy stock at the moment, with a recommendation rating of 1.3. None of the analysts rate the stock as a Sell, while none rate it as Overweight. None out of 3 have rated it as a Hold, with 3 advising it as a Buy. None have rated the stock as Underweight. The expected earnings per share for the stock is -$0.02.

Palatin Technologies, Inc. (NYSE:PTN) trade information

Sporting 2.27% in the green today, the stock has traded in the green over the last five days, with the highest price hit on Tuesday, Jun 23 when the PTN stock price touched $0.7 or saw a rise of 24.74%. Year-to-date, Palatin Technologies, Inc. shares have moved -32.65%, while the 5-day performance has seen it change 2.25%. Over the past 30 days, the shares of Palatin Technologies, Inc. (NYSE:PTN) have changed 3.93%. Short interest in the company has seen 21.16 Million shares shorted with days to cover at 8.82.

Wall Street analysts have a consensus price target for the stock at $2.17, which means that the shares’ value could jump 311.92% from current levels. The projected low price target is $1.5 while the price target rests at a high of $3. In that case, then, we find that the current price level is +469.48% off the targeted high while a plunge would see the stock lose 184.74% from current levels.

Palatin Technologies, Inc. (PTN) estimates and forecasts

Figures show that Palatin Technologies, Inc. shares have underperformed across the wider relevant industry. The company’s shares have lost -34.15% over the past 6 months, with this year growth rate of -156.25%, compared to 9.2% for the industry. Other than that, the company has, however, lowered its growth outlook for the 2020 fiscal year revenue. Growth estimates for the current quarter are -108.7% and 300% for the next quarter. Revenue growth from the last financial year stood is estimated to be -99.8%.

If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was +26.7% over the past 5 years. Earnings growth for 2020 is a modest +40.9% while over the next 5 years, the company’s earnings are expected to increase by 0%.